A Phase 3 interventional study of Bupivacaine 0.25% and Dexmedetomidine 1mcg/kg in Posterior Fossa Tumor, sponsored by Children's Cancer Hospital Egypt 57357. Recruiting at 1 site in Egypt. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Children's Cancer Hospital Egypt 57357 · Phase 3, Interventional, and Treatment
The goal of this clinical trial is to evaluate the effects of ultrasound-guided versus blind greater occipital nerve block (GONB), with or without Dexmedetomidine as an adjuvant, in pediatric patients undergoing posterior fossa tumor excision under general anesthesia.
The main questions it aims to answer are:
Researchers will compare four groups to evaluate the effects of the nerve block technique and the addition of dexmedetomidine:
Group A: Blind GONB using 0.25% bupivacaine. Group B: Blind GONB using 0.25% bupivacaine with dexmedetomidine (1 μg/kg). Group C: Ultrasound-guided GONB using 0.25% bupivacaine. Group D: Ultrasound-guided GONB using 0.25% bupivacaine with dexmedetomidine (1 μg/kg).
Participants will be pediatric patients scheduled for elective posterior fossa tumor excision at Children's Cancer Hospital Egypt (CCHE 57357). They will be randomly assigned to one of the four groups and will receive standardized general anesthesia and bilateral GONB according to their assigned group. Intraoperative heart rate and blood pressure, intraoperative and postoperative opioid consumption, and time to first postoperative rescue analgesia will be assessed.
21 studies on the registry are indexed under Infratentorial Neoplasms; 5 are open to participants now.
This study's planned enrollment of 260 is above the median of 50 across 11 interventional studies indexed under Infratentorial Neoplasms.
Browse Infratentorial Neoplasms studies →Children's Cancer Hospital Egypt 57357 is the lead sponsor of 21 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive a blind bilateral greater occipital nerve block using 0.25% Bupivacaine.
Drug: Bupivacaine 0.25% · Procedure: Blind greater occipital nerve block
Participants will receive a blind bilateral greater occipital nerve block using 0.25% Bupivacaine with Dexmedetomidine 1mcg/kg.
Drug: Bupivacaine 0.25% · Drug: Dexmedetomidine 1mcg/kg · Procedure: Blind greater occipital nerve block
Participants will receive an ultrasound-guided bilateral greater occipital nerve block using 0.25% Bupivacaine.
Drug: Bupivacaine 0.25% · Procedure: Ultrasound-guided greater occipital nerve block
Participants will receive an ultrasound-guided bilateral greater occipital nerve block using 0.25% Bupivacaine with Dexmedetomidine 1mcg/kg.
Drug: Bupivacaine 0.25% · Drug: Dexmedetomidine 1mcg/kg · Procedure: Ultrasound-guided greater occipital nerve block
Bupivacaine 0.25% will be used for bilateral greater occipital nerve block in pediatric patients undergoing posterior fossa tumor excision.
Drug page: Dexmedetomidine
Dexmedetomidine at a dose of 1 mcg/kg will be added to Bupivacaine 0.25%for bilateral greater occipital nerve block in pediatric patients undergoing posterior fossa tumor excision.
Bilateral greater occipital nerve block performed using the blind technique in pediatric patients undergoing posterior fossa tumor excision. .
Bilateral greater occipital nerve block performed under ultrasound guidance in pediatric patients undergoing posterior fossa tumor excision. .
mean arterial pressure (MAP)
mean arterial pressure will be assessed to evaluate the effects of ultrasound-guided versus blind greater occipital nerve block and using Dexmedetomidine as an adjuvant.
Time frame: Intraoperatively post nerve block injection
Heart rate (HR)
heart rate will be measured to assess hemodynamic responses following greater occipital nerve block.
Time frame: intraoperatively post nerve block injection
Intraoperative and postoperative opioid consumption
total opioid consumption intraoperatively and postoperatively will be assessed and compared among the four study groups
Time frame: during the surgery and postoperatively
time to first postoperative rescue analgesia
the time from completion of surgery to administration of the first rescue analgesic will be recorded to evaluate the duration of postoperative analgesia
Time frame: from the end of surgery to the administration of the first rescue analgesic
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Children's Cancer Hospital Egypt 57357